We are live on
!
Find out more
MC
Maverick Capital Portfolio holdings
AUM
$8.67B
1-Year Est. Return
48.76%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+48.76%
3 Year Est. Return
+198.74%
5 Year Est. Return
+110.99%
10 Year Est. Return
+397.6%
AUM
$4.22B
AUM Growth
-$216M
(-4.9%)
Cap. Flow
-$128M
Cap. Flow
% of AUM
-3.04%
Top 10 Holdings %
Top 10 Hldgs %
54.35%
Holding
468
New
124
Increased
152
Reduced
87
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$76.2M |
| 2 |
CBRE Group
CBRE
|
+$62.8M |
| 3 |
Jones Lang LaSalle
JLL
|
+$59.7M |
| 4 |
Meta Platforms (Facebook)
META
|
+$56.7M |
| 5 |
Applied Materials
AMAT
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coupang
CPNG
|
+$89.1M |
| 2 |
Humana
HUM
|
+$59.3M |
| 3 |
T-Mobile US
TMUS
|
+$57.7M |
| 4 |
Visa
V
|
+$52.7M |
| 5 |
ASZ.U
Austerlitz Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
ASZ.U
|
+$38.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 37.51% |
| 2 | Technology | 18.28% |
| 3 | Healthcare | 16% |
| 4 | Communication Services | 10.42% |
| 5 | Financials | 5.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Caleres
CAL
$431M
| $287K | 0.01% |
12,897
-12,687
| -50% | -$311K |
|
302
Teva Pharmaceuticals
TEVA
$40.8B
| $287K | 0.01% |
+31,449
| New | +$274K |
|
303
Mattel
MAT
$4.38B
| $286K | 0.01% |
16,044
+5,229
| +48% | +$94.8K |
|
304
Teladoc Health
TDOC
$1.22B
| $283K | 0.01% |
+11,976
| New | +$323K |
|
305
AbCellera Biologics
ABCL
$1.74B
| $280K | 0.01% |
27,637
+5,184
| +23% | +$59.9K |
|
306
Skyworks Solutions
SWKS
$9.37B
| $278K | 0.01% |
+3,055
| New | +$274K |
|
307
Ulta Beauty
ULTA
$22B
| $276K | 0.01% |
+589
| New | +$254K |
|
308
Adient
ADNT
$1.65B
| $276K | 0.01% |
+7,956
| New | +$278K |
|
309
Supernus Pharmaceuticals
SUPN
$2.59B
| $275K | 0.01% |
7,711
-1,175
| -13% | -$40.8K |
|
310
SLM Corp
SLM
$4.89B
| $273K | 0.01% |
16,465
+3,887
| +31% | +$63.7K |
|
311
Emerson Electric
EMR
$83.9B
| $272K | 0.01% |
2,833
-14,232
| -83% | -$1.28M |
|
312
Herbalife
HLF
$1.29B
| $271K | 0.01% |
+18,198
| New | +$317K |
|
313
Edwards Lifesciences
EW
$49.6B
| $270K | 0.01% |
3,622
-10,616
| -75% | -$818K |
|
314
Norfolk Southern
NSC
$75.4B
| $267K | 0.01% |
1,085
+131
| +14% | +$31K |
|
315
Bio-Rad Laboratories Class A
BIO
$8.71B
| $267K | 0.01% |
+635
| New | +$256K |
|
316
Lowe's Companies
LOW
$117B
| $266K | 0.01% |
1,337
-10,375
| -89% | -$2.07M |
|
317
Adeia
ADEA
$2.94B
| $266K | 0.01% |
+28,039
| New | +$285K |
|
318
Imperial Oil
IMO
$62.7B
| $265K | 0.01% |
+5,439
| New | +$280K |
|
319
East-West Bancorp
EWBC
$17.9B
| $263K | 0.01% |
+3,998
| New | +$274K |
|
320
Ovintiv
OVV
$17.3B
| $262K | 0.01% |
+5,174
| New | +$270K |
|
|
COOP
321
DELISTED
Mr. Cooper
COOP
| $262K | 0.01% |
6,522
+495
| +8% | +$20.9K |
|
322
Zions Bancorporation
ZION
$10.2B
| $261K | 0.01% |
+5,303
| New | +$265K |
|
323
Elevance Health
ELV
$81.5B
| $261K | 0.01% |
508
-36
| -7% | -$18.3K |
|
324
Bank of America
BAC
$435B
| $260K | 0.01% |
+7,864
| New | +$271K |
|
|
DOOR
325
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $260K | 0.01% |
+3,225
| New | +$238K |
|
Similar funds
PCIA
ACM
OAM
NB
IC
SWP
MOACM
MERSOM
Maverick Capital's Q4 2022 Portfolio in Review
As of Q4 2022, Maverick Capital held 468 positions worth $4.22B, down 4.9% from $4.44B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Maverick Capital withdrew a net $128M in Q4 2022, closing 91 positions and reducing 87 holdings. Its most notable exit was Austerlitz Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant, an estimated $38.8M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 38% of assets, down from 42% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Maverick Capital opened a new position in CATALENT, INC. worth $63.1M.
- Maverick Capital's largest Q4 2022 buy was CATALENT, INC.: 1,401,649 shares worth $63.1M.
- Maverick Capital added most to Jones Lang LaSalle in Q4 2022, an estimated $59.7M increase.
- Maverick Capital's biggest Q4 2022 reduction was Coupang, cutting an estimated $89.1M.
- Maverick Capital fully exited Austerlitz Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant in Q4 2022, selling an estimated $38.8M.
- Maverick Capital's ten largest holdings make up 54% of its $4.22B portfolio in Q4 2022.
- Maverick Capital opened 124 new positions and closed 91 in Q4 2022.
- Maverick Capital's portfolio value fell 4.9% quarter-over-quarter to $4.22B.
Based on Maverick Capital's 13F filing for Q4 2022, filed 14 Feb 2023.